ZBH Stock Recent News

Zimmer Biomet Holdings Inc on Tuesday beat Wall Street estimates for third-quarter profit, as a rebound in knee surgeries lifted demand for the medical device maker's products.

Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zimmer Biomet (ZBH) is expected to have witnessed strong performance across Avenir Complete hip.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Investors are optimistic about Zimmer Biomet (ZBH) on business recovery and expansion in emerging markets.

Zimmer Biomet (ZBH) plans to work on the overall shift of the company's legacy knee systems to a fully rounded-out Persona portfolio.

Zimmer Biomet Holdings outlined strategies to gain market share in the knee sector and foster innovation in hip products. ZBH has raised its 2023 growth forecast, reflecting confidence in its strategic initiatives. It also reported strong financial performance in Q2 2023, with increased sales and stable EPS.

Zimmer Biomet (ZBH) is benefiting from increased provider capacity, resulting in backlog pull-through in the recent quarters.

Investors are optimistic about Zimmer Biomet (ZBH) due to innovative new product launches and solid execution.